5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Serotonin O
Syndrome O
: O
Increased O
risk O
when O
co-administered O
with O
other O
serotonergic O
agents O
( O
e.g. O
, O
SSRI O
, O
SNRI O
, O
triptans O
) O
, O
but O
also O
when O
taken O
alone O
. O

If O
it O
occurs O
, O
discontinue O
VIIBRYD O
and O
initiate O
supportive O
treatment O
( O
5.2 O
) O
* O
Increased O
Risk O
of O
Bleeding O
: O
Concomitant O
use O
of O
aspirin O
, O
nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
, O
other O
antiplatelet O
drugs O
, O
warfarin O
, O
and O
other O
anticoagulants O
may O
increase O
this O
risk O
( O
5.3 O
) O
* O
Activation O
of O
Mania/Hypomania O
: O
Screen O
patients O
for O
bipolar O
disorder O
( O
5.4 O
) O
. O

* O
Seizures O
: O
Can O
occur O
with O
treatment O
. O

Use O
with O
caution O
in O
patients O
with O
a O
seizure O
disorder O
( O
5.6 O
) O
. O

* O
Angle O
Closure O
Glaucoma O
: O
Avoid O
use O
of O
antidepressants O
, O
including O
VIIBRYD O
, O
in O
patients O
with O
untreated O
anatomically O
narrow O
angles O
. O

( O
5.7 O
) O
5.1 O
Suicidal O
Thoughts O
and O
Behavior O
in O
Children O
, O
Adolescents O
and O
Young O
Adults O
In O
pooled O
analyses O
of O
placebo-controlled O
trials O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
other O
antidepressant O
classes O
) O
that O
included O
approximately O
77,000 O
adult O
patients O
, O
and O
over O
4,400 O
pediatric O
patients O
, O
the O
incidence O
of O
suicidal B-OSE_Labeled_AE
thoughts O
and O
behaviors I-OSE_Labeled_AE
in O
patients O
age O
24 O
years O
and O
younger O
was O
greater O
in O
antidepressant-treated O
patients O
than O
in O
placebo-treated O
patients O
. O

The O
drug-placebo O
differences O
in O
the O
number O
of O
cases O
of O
suicidal B-NonOSE_AE
thoughts O
and O
behaviors I-NonOSE_AE
per O
1000 O
patients O
treated O
are O
provided O
in O
Table O
1 O
. O

No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
studies O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
studies O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
antidepressant O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

Table O
1 O
: O
Risk O
Differences O
of O
the O
Number O
of O
Patients O
with O
Suicidal O
Thoughts O
or O
Behaviors O
in O
the O
Pooled O
Placebo-Controlled O
Trials O
of O
Antidepressants O
in O
Pediatric O
and O
Adult O
Patients O
Age O
Range O
( O
years O
) O
Drug-Placebo O
Difference O
in O
Number O
of O
Patients O
with O
Suicidal B-OSE_Labeled_AE
Thoughts I-OSE_Labeled_AE
or O
Behaviors O
per O
1000 O
Patients O
Treated O
Increases O
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
patients O
18-24 O
5 O
additional O
patients O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
patient O
> O
=65 O
6 O
fewer O
patients O
It O
is O
unknown O
whether O
the O
risk O
of O
suicidal B-NonOSE_AE
thoughts O
and O
behaviors I-NonOSE_AE
in O
children O
, O
adolescents O
, O
and O
young O
adults O
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
four O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
studies O
in O
adults O
with O
MDD B-Not_AE_Candidate
that O
antidepressants O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

Monitor O
all O
antidepressant-treated O
patients O
for O
clinical O
worsening O
and O
emergence O
of O
suicidal B-NonOSE_AE
thoughts O
and O
behaviors I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
drug O
therapy O
and O
at O
times O
of O
dosage O
changes O
. O

Counsel O
family O
members O
or O
caregivers O
of O
patients O
to O
monitor O
for O
changes O
in O
behavior O
and O
to O
alert O
the O
healthcare O
provider O
. O

Consider O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
VIIBRYD O
, O
in O
patients O
whose O
depression B-Not_AE_Candidate
is O
persistently O
worse O
, O
or O
who O
are O
experiencing O
emergent O
suicidal B-NonOSE_AE
thoughts O
or O
behaviors I-NonOSE_AE
. O

5.2 O
Serotonin O
Syndrome O
SNRIs O
and O
SSRIs O
, O
including O
VIIBRYD O
, O
can O
precipitate O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
a O
potentially O
life-threatening O
condition O
. O

The O
risk O
is O
increased O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
and O
St O
. O
John O
's O
Wort O
) O
and O
with O
drugs O
that O
impair O
metabolism O
of O
serotonin O
, O
i.e. O
, O
MAOIs O
[ O
see O
Contraindications O
( O
4 O
) O
and O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
can O
also O
occur O
when O
these O
drugs O
are O
used O
alone O
. O

Symptoms O
of O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
were O
noted O
in O
0.1 O
% O
of O
MDD B-Not_AE_Candidate
patients O
treated O
with O
VIIBRYD O
in O
premarketing O
clinical O
trials O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
signs O
and O
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
and O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
, O
seizures B-NonOSE_AE
, O
and O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

The O
concomitant O
use O
of O
VIIBRYD O
with O
MAOIs O
is O
contraindicated O
. O

In O
addition O
, O
do O
not O
initiate O
VIIBRYD O
in O
a O
patient O
being O
treated O
with O
MAOIs O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
. O

No O
reports O
involved O
the O
administration O
of O
methylene O
blue O
by O
other O
routes O
( O
such O
as O
oral O
tablets O
or O
local O
tissue O
injection O
) O
. O

If O
it O
is O
necessary O
to O
initiate O
treatment O
with O
an O
MAOI O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
in O
a O
patient O
taking O
VIIBRYD O
, O
discontinue O
VIIBRYD O
before O
initiating O
treatment O
with O
the O
MAOI O
[ O
see O
Contraindications O
( O
4 O
) O
, O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

Monitor O
all O
patients O
taking O
VIIBRYD O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

Discontinue O
treatment O
with O
VIIBRYD O
and O
any O
concomitant O
serotonergic O
agents O
immediately O
if O
the O
above O
symptoms O
occur O
, O
and O
initiate O
supportive O
symptomatic O
treatment O
. O

If O
concomitant O
use O
of O
VIIBRYD O
with O
other O
serotonergic O
drugs O
is O
clinically O
warranted O
, O
inform O
patients O
of O
the O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
and O
monitor O
for O
symptoms O
. O

5.3 O
Increased O
Risk O
of O
Bleeding O
Drugs O
that O
interfere O
with O
serotonin O
reuptake O
inhibition O
, O
including O
VIIBRYD O
, O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
events O
. O

Concomitant O
use O
of O
aspirin O
, O
nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAIDS O
) O
, O
other O
antiplatelet O
drugs O
, O
warfarin O
, O
and O
other O
anticoagulants O
may O
add O
to O
this O
risk O
. O

Case O
reports O
and O
epidemiological O
studies O
( O
case-control O
and O
cohort O
design O
) O
have O
demonstrated O
an O
association O
between O
use O
of O
drugs O
that O
interfere O
with O
serotonin O
reuptake O
and O
the O
occurrence O
of O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
. O

Bleeding B-OSE_Labeled_AE
events O
related O
to O
drugs O
that O
interfere O
with O
serotonin O
reuptake O
have O
ranged O
from O
ecchymosis B-OSE_Labeled_AE
, O
hematoma B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
petechiae B-OSE_Labeled_AE
to O
life-threatening O
hemorrhages B-OSE_Labeled_AE
. O

Inform O
patients O
about O
the O
risk O
of O
bleeding B-NonOSE_AE
associated O
with O
the O
concomitant O
use O
of O
VIIBRYD O
and O
antiplatelet O
agents O
or O
anticoagulants O
. O

For O
patients O
taking O
warfarin O
, O
carefully O
monitor O
coagulation O
indices O
when O
initiating O
, O
titrating O
, O
or O
discontinuing O
VIIBRYD O
. O

5.4 O
Activation O
of O
Mania O
or O
Hypomania O
In O
patients O
with O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
treating O
a O
depressive B-Not_AE_Candidate
episode I-Not_AE_Candidate
with O
VIIBRYD O
or O
another O
antidepressant O
may O
precipitate O
a O
mixed B-OSE_Labeled_AE
/manic O
episode I-OSE_Labeled_AE
. O

In O
controlled O
clinical O
trials O
, O
patients O
with O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
were O
excluded O
; O
however O
, O
symptoms O
of O
mania B-OSE_Labeled_AE
or O
hypomania B-OSE_Labeled_AE
were O
reported O
in O
0.1 O
% O
of O
undiagnosed O
patients O
treated O
with O
VIIBRYD O
. O

Prior O
to O
initiating O
treatment O
with O
VIIBRYD O
, O
screen O
patients O
for O
any O
personal O
or O
family O
history O
of O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
mania B-Not_AE_Candidate
, O
or O
hypomania B-Not_AE_Candidate
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.5 O
Discontinuation O
Syndrome O
Adverse B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
after I-OSE_Labeled_AE
discontinuation I-OSE_Labeled_AE
of O
serotonergic O
antidepressants O
, O
particularly O
after O
abrupt O
discontinuation O
, O
include O
: O
nausea B-NonOSE_AE
, O
sweating B-NonOSE_AE
, O
dysphoric B-NonOSE_AE
mood I-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
sensory B-NonOSE_AE
disturbances I-NonOSE_AE
( O
e.g. O
, O
paresthesia B-NonOSE_AE
, O
such O
as O
electric B-NonOSE_AE
shock I-NonOSE_AE
sensations I-NonOSE_AE
) O
, O
tremor B-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
emotional B-NonOSE_AE
lability I-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
hypomania B-NonOSE_AE
, O
tinnitus B-NonOSE_AE
, O
and O
seizures B-NonOSE_AE
. O

A O
gradual O
reduction O
in O
dosage O
rather O
than O
abrupt O
cessation O
is O
recommended O
whenever O
possible O
[ O
see O
Dosage O
and O
Administration O
( O
2.5 O
) O
] O
. O

5.6 O
Seizures O
VIIBRYD O
has O
not O
been O
systematically O
evaluated O
in O
patients O
with O
a O
seizure B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
were O
excluded O
from O
clinical O
studies O
. O

VIIBRYD O
should O
be O
prescribed O
with O
caution O
in O
patients O
with O
a O
seizure B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

5.7 O
Angle-Closure O
Glaucoma O
The O
pupillary B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
that O
occurs O
following O
use O
of O
many O
antidepressant O
drugs O
including O
VIIBRYD O
may O
trigger O
an O
angle B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
in O
a O
patient O
with O
anatomically B-Not_AE_Candidate
narrow I-Not_AE_Candidate
angles I-Not_AE_Candidate
who O
does O
not O
have O
a O
patent O
iridectomy O
. O

Avoid O
use O
of O
antidepressants O
, O
including O
VIIBRYD O
, O
in O
patients O
with O
untreated O
anatomically B-Not_AE_Candidate
narrow I-Not_AE_Candidate
angles I-Not_AE_Candidate
. O

5.8 O
Hyponatremia O
Hyponatremia B-OSE_Labeled_AE
may O
occur O
as O
a O
result O
of O
treatment O
with O
SNRIs O
and O
SSRIs O
, O
including O
VIIBRYD O
. O

Cases O
of O
serum B-OSE_Labeled_AE
sodium I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
have O
been O
reported O
. O

Signs O
and O
symptoms O
of O
hyponatremia B-NonOSE_AE
include O
headache B-NonOSE_AE
, O
difficulty B-NonOSE_AE
concentrating I-NonOSE_AE
, O
memory B-NonOSE_AE
impairment I-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
and O
unsteadiness B-NonOSE_AE
, O
which O
may O
lead O
to O
falls B-NonOSE_AE
. O

Signs O
and O
symptoms O
associated O
with O
more O
severe O
and/or O
acute O
cases O
have O
included O
hallucination B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
coma B-NonOSE_AE
, O
respiratory B-NonOSE_AE
arrest I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

In O
many O
cases O
, O
this O
hyponatremia B-OSE_Labeled_AE
appears O
to O
be O
the O
result O
of O
the O
syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
antidiuretic I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
( O
SIADH O
) O
. O

In O
patients O
with O
symptomatic O
hyponatremia B-NonOSE_AE
, O
discontinue O
VIIBRYD O
and O
institute O
appropriate O
medical O
intervention O
. O

Elderly O
patients O
, O
patients O
taking O
diuretics O
, O
and O
those O
who O
are O
volume B-Not_AE_Candidate
- I-Not_AE_Candidate
depleted I-Not_AE_Candidate
may O
be O
at O
greater O
risk O
of O
developing O
hyponatremia B-NonOSE_AE
with O
SSRIs O
and O
SNRIs O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.5 O
) O
] O
. O

